Advancing new therapeutic targets into innovative drugs is a major translational bottleneck in the southwestern United States. To address this urgent need, we aim to build a critical resource closing major medicinal chemistry resource gaps for our regional drug discovery scientific community. Towards this end, our project aims to deploy the Southwest Comprehensive Center for Drug Discovery and Development (SCCDD) which will provide an enabling collaborative framework for translating basic scientific findings into the clinic. By extension it is envisioned the Center will have resourced interdisciplinary capabilities with an industrialized approach to medicinal chemistry that is more likely to have a significant impact on healthcare. This multiple PI effort assembles existing interdisciplinary teams of scientists with complementary skill sets and significant industry experience. To ensure that the SCCDD can provide a comprehensive offering, we will leverage TGen's existing drug discovery and development infrastructure and strategically network chemistry innovations at the UA. The team has an established reputation and track record of collaboration, and shares a common focused mission: to modernize drug discovery by strategically aligning technological innovations and access to enabeling resources that collectively facilitates more efficient delivery of more effective treatments for the patients in need. The objective of this """"""""Grand Opportunity"""""""" is to deploy the necessary infrastructure and resources to reach Center operation status in a two year timeframe. To achieve this objective, we will build an Arizona compound collection, utilizing innovative enabling chemistry, high-throughput screening resources, and a dedicated medicinal chemistry team, overall establishing a functioning flowchart to rapidly expedite compound progression along the value chain. Four units will ensure the process flow as follows. Molecular probe or hit generation will be pursued by a library design, development, and production unit (Unit 1) working in concert with a high-throughput / content screening unit (Unit 2). The capabilities will be completed with a specialized medicinal chemistry unit (Unit 3) operating in either singleton or batch modalities to facilitate compound progression into efficacious molecules with potential for clinical evaluation. These three scientific Units will be supported by an administrative core (Unit 4) managing the target portfolio, making executive decisions for target progression, following projects, and developing strategic partnerships with academic collaborators or biotech/pharma. The SCCDD will leverage innovative technologies taking advantage of synergistic efficiencies in compound synthesis, computation, and screening, for more effective discovery of novel small molecules enabling the translation of targets from multiple therapeutic areas including - but not limited to - neoplastic, metabolic, cardiovascular, immunological, and neurological disease areas. In short, by creating a translational medicinal chemistry presence in the Southwest, the SCCDD infrastructure and resources will widely enable a functional drug discovery process in academic circles and local industry.

Public Health Relevance

The common goal of this proposal is to leverage currently existing high-throughput screening facilities at TGen by building medicinal chemistry infrastructure and library resources at the University of Arizona, leading to the formation of a collaborative, cross-disciplinary network named """"""""the Southwest Comprehensive Center for Drug Discovery and Development"""""""". The Center will accelerate the translation of basic scientific findings delivering molecular probes and developing them into more advanced molecules in a broad range of disease areas. The collective team consists of knowledgeable experts with experience ranging from government, academia, biotech and the pharmaceutical sector, sharing the critical mindset of discovering novel therapeutics for the patient in the most expeditious manner possible.

Agency
National Institute of Health (NIH)
Institute
National Institute of Mental Health (NIMH)
Type
High Impact Research and Research Infrastructure Programs (RC2)
Project #
1RC2MH090878-01
Application #
7855374
Study Section
Special Emphasis Panel (ZRG1-HDM-E (99))
Program Officer
Winsky, Lois M
Project Start
2009-09-30
Project End
2011-08-31
Budget Start
2009-09-30
Budget End
2010-08-31
Support Year
1
Fiscal Year
2009
Total Cost
$4,851,480
Indirect Cost
Name
Translational Genomics Research Institute
Department
Type
DUNS #
118069611
City
Phoenix
State
AZ
Country
United States
Zip Code
85004
Ayaz, Muhammad; Xu, Zhigang; Hulme, Christopher (2014) Novel succinct routes to Quinoxalines and 2-Benzimidazolylquinoxalines via the Ugi reaction. Tetrahedron Lett 55:3406-3409
Martin, Katie R; Narang, Pooja; Medina-Franco, José L et al. (2014) Integrating virtual and biochemical screening for protein tyrosine phosphatase inhibitor discovery. Methods 65:219-28
Dhruv, Harshil; Loftus, Joseph C; Narang, Pooja et al. (2013) Structural basis and targeting of the interaction between fibroblast growth factor-inducible 14 and tumor necrosis factor-like weak inducer of apoptosis. J Biol Chem 288:32261-76
Shaw, Arthur Y; Medda, Federico; Hulme, Christopher (2012) Facile and rapid route for the synthesis of novel conformationally constrained norstatine analogs via PADAM-cyclization methodology. Tetrahedron Lett 53:1313-1315
Xu, Zhigang; Shaw, Arthur Y; Nichol, Gary S et al. (2012) Applications of ortho-phenylisonitrile and ortho-N-Boc aniline for the two-step preparation of novel bis-heterocyclic chemotypes. Mol Divers 16:607-12
Shaw, Arthur Y; McLaren, Jonathan A; Nichol, Gary S et al. (2012) Hydrazine-mediated cyclization of Ugi products to synthesize novel 3-hydroxypyrazoles. Tetrahedron Lett 53:2592-2594
Petit, Joachim; Meurice, Nathalie; Kaiser, Christine et al. (2012) Softening the Rule of Five--where to draw the line? Bioorg Med Chem 20:5343-51
Xu, Zhigang; Shaw, Arthur Y; Dietrich, Justin et al. (2012) Facile, novel two-step syntheses of benzimidazoles, bis-benzimidazoles, and bis-benzimidazole-dihydroquinoxalines. Mol Divers 16:73-9
Xu, Zhigang; De Moliner, Fabio; Cappelli, Alexandra P et al. (2012) Ugi/aldol sequence: expeditious entry to several families of densely substituted nitrogen heterocycles. Angew Chem Int Ed Engl 51:8037-40
Shaw, Arthur Y; Xu, Zhigang; Hulme, Christopher (2012) Ugi/Robinson-Gabriel reactions directed toward the synthesis of 2,4,5-trisubstituted oxazoles. Tetrahedron Lett 53:1998-2000

Showing the most recent 10 out of 14 publications